enGene Therapeutics (ENGN)
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medici...
- Open
- 1.790
- High
- 1.830
- Low
- 1.750
- Prev. Close
- 1.780
- Volume
- 642.50K
- Turnover
- 1.16M
- Avg Price
- 1.800
- Bid/Ask Ratio
- --
- Amplitude
- 4.49%
- 52wk High
- 12.250
- Volume Ratio
- 0.85
- Turnover Ratio
- 1.96%
enGene Therapeutics Analyst Rating
View moreForecast & Rating
Aug 12, 2026Price forecast
$3.2981.53%
Forecast & RatingHold
10analysts
- Strong buy20.00%
- Buy10.00%
- Hold60.00%
- Sell10.00%
- Strong sell0.00%
News
- TradingView · Aug 15 at 03:20 PM
enGene Therapeutics Inc. Stock 12‑Month Price Target Cut to $3.43, Implies 102% Upside
- Market Beat · Aug 13 at 10:07 AM
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
- Quartr · Aug 11 at 10:06 AM
ENGN: Detalimogene's strong clinical profile and market fit position it for broad NMIBC adoption
- PUBT · Jul 22 at 03:06 PM
enGene Therapeutics files Form 3 for SVP Finance, Treasurer Kathleen P. Richton
- Tip Ranks · Jul 17 at 04:34 PM
enGene Highlights Progress of Lead Bladder Cancer Therapy
- PUBT · Jul 16 at 07:03 AM
enGene names Michael Heffernan board chairman as Richard Glickman steps down
